MedTrace Logo

Low Dose Radiotherapy in COVID-19 Pneumonia

NCT04390412 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2020-11-10

No results posted yet for this study

Summary

Moderate to severe cases of SARS-associated ARDS based on inclusion/ exclusion criteria and the decision made in multi- disciplinary team are treated with 0.5 Gy whole lung radiation.

Conditions

  • COVID
  • SARS (Severe Acute Respiratory Syndrome)

Interventions

RADIATION

Low Dose Radiotherapy

0.5 Gy radiation to both lungs in an AP/PA treatment plan

Sponsors & Collaborators

  • Shahid Beheshti University of Medical Sciences

    lead OTHER

Principal Investigators

  • Ahmad Ameri, Prof. · Shahid Beheshti University of Medical Sciences

  • Nazanin Rahnama, M.D. · Shahid Beheshti University of Medical Sciences

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-04
Primary Completion
2020-08-30
Completion
2020-12-31

Countries

  • Iran

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04390412 on ClinicalTrials.gov